Understanding a 1.7 cm Adrenal Adenoma: What to Expect

An adrenal incidentaloma is an asymptomatic adrenal mass discovered on imaging performed for unrelated reasons. A 1.7 cm lesion falls in the small (<4 cm) category, where the vast majority are benign, nonfunctional adenomas. However, systematic evaluation is essential.

Initial Evaluation Framework

1. Hormonal Workup (Mandatory for All)

• Cortisol excess (Cushing's): 1-mg overnight dexamethasone suppression test (DST) — cortisol <1.8 µg/dL excludes. Late-night salivary cortisol (2×) or 24-hr UFC.
• Primary aldosteronism (Conn's): Plasma aldosterone concentration (PAC) / plasma renin activity (PRA) ratio (ARR) — screen if hypertensive, hypokalemic, or resistant HTN.
• Pheochromocytoma: Plasma free metanephrines or 24-hr urine fractionated metanephrines — high sensitivity.
• Androgen excess: DHEA-S, testosterone if virilization signs.

2. Imaging Characterization

• CT with washout: Non-contrast HU <10 = lipid-rich adenoma (benign). Absolute washout >60% or relative >40% = adenoma.
• MRI chemical shift: Signal drop on out-of-phase = intracellular lipid = adenoma.
• Size: 1.7 cm is small; <1 cm often not worked up unless hormonal signs. ≥4 cm → surgical referral (malignancy risk ↑).

3. Clinical Context

• Age, sex, hypertension, hypokalemia, diabetes, family history (MEN, Li-Fraumeni, VHL, NF1).
• Medications affecting testing (estrogen, spironolactone, beta-blockers, antidepressants).

Management Pathways

Follow-Up Schedule (Typical)

• Baseline: Hormonal panel + dedicated adrenal CT/MRI.
• 6–12 months: Repeat imaging (size, morphology).
• Annually × 2 years if stable.
• Hormonal recheck only if new symptoms (HTN, hypokalemia, Cushingoid features).

Key Points

• 1.7 cm adenoma is overwhelmingly likely benign and nonfunctional.
• "Incidentaloma" ≠ "ignore" — hormonal exclusion is mandatory.
• Lipid-rich on imaging = virtually 100% benign.
• Surgery reserved for functional tumors, size ≥4 cm, growth, or imaging suspicion.
• Consult an endocrinologist for personalized plan.

Most patients with a 1.7 cm adrenal adenoma need only reassurance and a few follow-up scans.

Brain Tumors - Related Articles

• Benign vs. Malignant Brain Tumors: Key Differences in Behavior and Outcome
• Skull X-Ray: Procedure, Uses, Risks, and Benefits
• Short-Term Memory After Brain Tumor Surgery: Understanding and Recovery
• Focal Brain Tumor Symptoms: Causes, Signs & What to Do
• Meningioma Symptoms: Understanding Signs & Symptoms
• Pontine Glioma in Adults: Symptoms, Diagnosis & Understanding
• Stable Brain MRI: What It Means for Disease Progression and Treatment

Brain Tumors

• Brain Lesion vs. Brain Tumor: Key Differences and What They Mean
• Cerebral Tumors: Understanding Types, Symptoms & Diagnosis
• Traumatic Brain Injury (TBI): Causes, Symptoms, Diagnosis, and Recovery
• Non-Surgical Brain Cancer Treatment Options
• CT Scans: Understanding Potential Risks and Limitations
• Brain Tumor Symptoms: Recognizing Warning Signs & Seeking Help
• Glioblastoma: Causes, Risk Factors & Treatment Challenges
• Fetal Seizures (In Utero Seizures): Causes, Diagnosis & Prognosis
• Understanding Radiation's Impact on the Brain: Effects & Recovery
• Headaches, Dizziness, and Nausea: Understanding Potential Causes
• Understanding and Managing Pituitary Tumors: Symptoms & Treatment
• Brain MRI Cost: Factors, Estimates & How to Get an Accurate Quote

Health Sciences © https://www.222health.com

Finding	Action
Nonfunctional, lipid-rich, <4 cm, stable	Surveillance: repeat imaging at 6–12 mo, then annually × 1–2 yr; hormonal recheck if clinical change
Nonfunctional, indeterminate imaging	Short-interval follow-up (3–6 mo) or PET-CT if high suspicion
Functional (hormone excess)	Endocrine referral; surgery (adrenalectomy) for Cushing's, pheo, Conn's (if unilateral)
Growth >1 cm/year or suspicious features	Surgical referral (laparoscopic adrenalectomy)